Hide metadata

dc.date.accessioned2021-04-22T19:33:40Z
dc.date.available2021-04-22T19:33:40Z
dc.date.created2020-10-16T11:23:27Z
dc.date.issued2020
dc.identifier.citationHarris, Gerd Marie Eskerud Wood, Mollie Nordeng, Hedvig Marie Egeland . Modeling exposures of medications used episodically during pregnancy: Triptans as a motivating example. Pharmacoepidemiology and Drug Safety. 2020, 29(9), 1111-1119
dc.identifier.urihttp://hdl.handle.net/10852/85466
dc.description.abstractPurpose To assess the validity of dispensed prescription to classify exposure to medications used episodically during pregnancy, and to explore individual trajectories of episodic medication use across pregnancy, using triptans for migraine as the motivating example. Methods We compared self‐reported triptan use during pregnancy in The Norwegian Mother, Father and Child Cohort Study (MoBa) to dispensed prescriptions in The Norwegian Prescription Database and calculated Cohen's kappa coefficient (κ), sensitivity, specificity and predictive values using MoBa as reference standard. We used group‐based trajectory modeling to estimate exposure trajectories in MoBa according to probability of triptan use across pregnancy. Results We identified 6051 pregnancies where mothers filled at least one triptan prescription or reported migraine or triptan use in the 6 months before or during pregnancy. Sensitivity of prescribed triptans during pregnancy was low (39.1%), but specificity was quite high (95.4%). Agreement between the two data sources was fair (κ 0.36). We identified three trajectory groups in MoBa including constant‐high, decreasing‐medium and decreasing‐low probability of triptan use across pregnancy. Conclusions Using dispensed prescriptions rather than self‐report to classify exposure to triptans during pregnancy is likely to result in substantial under‐estimation of exposure. In this study, traditional definitions of ever‐exposed vs never‐exposed failed to capture variations in drug utilization during pregnancy.
dc.languageEN
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleModeling exposures of medications used episodically during pregnancy: Triptans as a motivating example
dc.typeJournal article
dc.creator.authorHarris, Gerd Marie Eskerud
dc.creator.authorWood, Mollie
dc.creator.authorNordeng, Hedvig Marie Egeland
cristin.unitcode185,15,23,10
cristin.unitnameGalenisk farmasi og samfunnsfarmasi
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.cristin1840108
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Pharmacoepidemiology and Drug Safety&rft.volume=29&rft.spage=1111&rft.date=2020
dc.identifier.jtitlePharmacoepidemiology and Drug Safety
dc.identifier.volume29
dc.identifier.issue9
dc.identifier.startpage1111
dc.identifier.endpage1119
dc.identifier.doihttps://doi.org/10.1002/pds.5089
dc.identifier.urnURN:NBN:no-88159
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn1053-8569
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/85466/1/Harris_2020_Mod.pdf
dc.type.versionPublishedVersion
dc.relation.projectEC/H2020/678033


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial-NoDerivatives 4.0 International
This item's license is: Attribution-NonCommercial-NoDerivatives 4.0 International